Provided by Tiger Trade Technology Pte. Ltd.

Cytokinetics

72.45
-1.3200-1.79%
Post-market: 73.000.5500+0.76%19:30 EDT
Volume:1.53M
Turnover:112.29M
Market Cap:10.07B
PE:-10.09
High:74.65
Open:73.51
Low:72.34
Close:73.77
52wk High:88.31
52wk Low:47.22
Shares:139.02M
Float Shares:138.02M
Volume Ratio:1.00
T/O Rate:1.11%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-7.1827
EPS(LYR):-6.5400
ROE:-572.15%
ROA:-28.09%
PB:-58.06
PE(LYR):-11.08

Loading ...

Cytokinetics EVP R&D Malik Fady Ibraham disposes 3,500 shares worth $270,795

Reuters
·
May 06

Cytokinetics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 06

BRIEF-Cytokinetics Inc - Offers Common Stock With Aggregate Public Offering Price Of $650 Million - SEC Filing

Reuters
·
May 06

Cytokinetics Inc - Offers Common Stock With Aggregate Public Offering Price of $650 Mln - SEC Filing

THOMSON REUTERS
·
May 06

Cytokinetics plans $650 million common stock offering

Reuters
·
May 06

Earnings Flash (CYTK) Cytokinetics Posts Q1 Loss $1.67, vs. FactSet Est of $1.65 Loss

MT Newswires Live
·
May 06

Cytokinetics Highlights MYQORZO Progress and Cardiology Pipeline

TIPRANKS
·
May 06

Cytokinetics Q1 revenue jumps on MYQORZO launch

Reuters
·
May 06

Cytokinetics director Wendell Wierenga sells 4,032 shares for $302,400

Reuters
·
May 06

Cytokinetics Q1 EPS $(1.67) Misses $(1.64) Estimate, Sales $19.355M Beat $8.518M Estimate.

Benzinga Earnings
·
May 06

Cytokinetics CFO Sung Lee sells 23,906 shares for $1.84 million

Reuters
·
May 06

Cytokinetics Inc - Announces Proposed $650 Mln Common Stock Offering

THOMSON REUTERS
·
May 06

Cytokinetics EVP, Chief Commercial Officer Andrew Callos disposes 11,333 shares for $875,372.25

Reuters
·
May 06

BRIEF-Cytokinetics Q1 Basic EPS USD -1.67

Reuters
·
May 06

Cytokinetics Reports First Quarter 2026 Financial Results and Provides Business Update

GlobeNewswire
·
May 06

Cytokinetics Is Maintained at Buy by Needham

Dow Jones
·
May 06

Cytokinetics Shares Surge Over 20% on Positive Heart Drug Trial Results

Stock News
·
May 05

Cytokinetics price target raised to $106 from $92 at Truist

TIPRANKS
·
May 05

Cytokinetics report ‘arguably a best-case scenario’ for Edgewise, says Stifel

TIPRANKS
·
May 05

Cytokinetics Phase 3 data bodes well for Edgewise, says Raymond James

TIPRANKS
·
May 05